Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 11/20 | 0.68 |
| ▸ | SLC6A4 | P31645 | 11/20 | 0.68 |
| ▸ | SLC6A2 | P23975 | 5/20 | 0.54 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.49 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.43 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8350798 | 0.84 | SLC6A4 (0.47) | SLC6A3SLC6A4SLC6A2 | |
| SCHEMBL17832228 | 0.82 | SLC6A4 (0.96) | SLC6A3SLC6A4SLC6A2HSD11B1 | |
| SCHEMBL3518031 | 0.81 | SLC6A4 (1.00) | SLC6A3SLC6A4SLC6A2HSD11B1 | |
| SCHEMBL16408076 | 0.81 | SLC6A4 (0.69) | SLC6A3SLC6A4SLC6A2 | |
| SCHEMBL17788480 | 0.79 | SLC6A4 (0.61) | SLC6A3SLC6A4SLC6A2 | |
| SCHEMBL13539472 | 0.77 | SLC6A4 (0.58) | SLC6A3SLC6A4SLC6A2OPRM1 | |
| SCHEMBL12000478 | 0.76 | SLC6A3 (0.54) | SLC6A3SLC6A4SLC6A2HSD11B1OPRM1 | |
| SCHEMBL12000464 | 0.75 | SLC6A3 (0.57) | SLC6A3SLC6A4SLC6A2HSD11B1OPRM1 | |
| SCHEMBL14944312 | 0.73 | SLC6A3 (0.59) | SLC6A3SLC6A4SLC6A2HSD11B1CACNA1G | |
| SCHEMBL12000469 | 0.72 | SLC6A3 (0.54) | SLC6A3SLC6A4SLC6A2HSD11B1OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9775831-B2 | Combinations comprising biphenyl derivatives for use in the treatment of HCV | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-10-03 | — | — | US | disclosed |
| US-9775831-B2 | Combinations comprising biphenyl derivatives for use in the treatment of HCV | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-10-03 | — | — | US | disclosed |
| US-20160166545-A1 | COMBINATIONS COMPRISING BIPHENYL DERIVATIVES FOR USE IN THE TREATMENT OF HCV | BRISTOL MYERS SQUIBB CO (US) | 2016-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160166545-A1 | COMBINATIONS COMPRISING BIPHENYL DERIVATIVES FOR USE IN THE TREATMENT OF HCV | HAVCR2, EIF2AK2, MAVS | SLC6A3 3276/4885SLC6A4 3872/4885SLC6A2 4319/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.